U.S. market Closed. Opens in 2 days 3 hours 54 minutes

ENZ | Enzo Biochem, Inc. Stock Fundamentals

(Stock Exchange: NYSE)
Analyzing fundamentals for ENZ we got that it has average fundamentals where Valuation is considered to be slightly overvalued, Profitability is stunning wealthy, Growth is desperately bad and Health is weak.

Valuation (47%)

Company Industry
P/E Ratio (TTM) 1.28 34.85
PEG Ratio (TTM) 0.01 -7.67
P/S Ratio (TTM) 12.21 6.49
P/B Ratio (TTM) 0.83 1.62
P/FCF Ratio (TTM) -1.33 23.09
Price to 5YR AVG Earnings Ratio -2.02 128.58
Price to 5YR AVG FCF Ratio -3.33 95.20

Profitability (85%)

Company Industry
ROA (TTM) 47.86% 5.04%
ROE (TTM) 61.16% 0.90%
Net Profit Margin (TTM) 947.53% 11.19%
ROIC 5YR AVG 11.60% 11.42%

Growth (22%)

4QTR AVG 3YR AVG 5YR AVG
EPS 21.84% -224.65% -319.40%
Revenue -19.75% 8.68% -10.80%
Net Income 108.37% -227.10% -250.13%
Cash Flow -28.59% -26.49% -917.84%

Health (49%)

Company Industry
Current Ratio (TTM) 3.50 1.74
Quick Ratio (TTM) 3.16 1.30
D/E Ratio (TTM) 0.07 -1.20
Interest Coverage (TTM) -0.66 -26.34
Piotroski F-Score 4 5
Altman Z-Score N/A 12.51
LTL to 5YR AVG FCF -0.20 3.03
Shares Outstanding Growth 5YR AVG 0.92% 1.33%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙